Literature DB >> 23130662

Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology.

Babita Shashni1, Kishore R Sakharkar, Yukio Nagasaki, Meena K Sakharkar.   

Abstract

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor and plays important roles in breast cancer cell proliferation. The complexity of the underlying biochemical and molecular mechanisms of breast cancer and the involvement of PPARγ in breast cancer pathophysiology are unclear. In this study, we carried out prediction of the peroxisome proliferator response element (PPRE) motifs in 2332 genes reported to be involved in breast cancer in literature. A total of 178 genes were found to have PPRE (DR1/DR2) and/or PPAR-associated conserved motif (PACM) motifs. We further constructed protein-protein interaction network, disease gene network and gene ontology (GO) analyses to identify novel key genes for experimental validation. We identified two genes in the glycolytic pathway (phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2)) at the ATP production steps and experimentally validated their repression by PPARγ in two breast cancer cell lines MDA-MB-231 and MCF-7. Further analysis suggested that this repression leads to decrease in ATP levels and apoptosis. These investigations will help us in understanding the molecular mechanisms by which PPARγ regulates the cellular energy pathway and the use of its ligands in human breast cancer therapeutics.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23130662     DOI: 10.3109/1061186X.2012.736998

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  22 in total

1.  Proteomic characterization of peroxisome proliferator-activated receptor-γ (PPARγ) overexpressing or silenced colorectal cancer cells unveils a novel protein network associated with an aggressive phenotype.

Authors:  Maria Rita Milone; Biagio Pucci; Tommaso Colangelo; Rita Lombardi; Federica Iannelli; Vittorio Colantuoni; Lina Sabatino; Alfredo Budillon
Journal:  Mol Oncol       Date:  2016-07-25       Impact factor: 6.603

Review 2.  PGK1-mediated cancer progression and drug resistance.

Authors:  Yu He; Yang Luo; Dan Zhang; Xixi Wang; Peng Zhang; Haocheng Li; Samina Ejaz; Shufang Liang
Journal:  Am J Cancer Res       Date:  2019-11-01       Impact factor: 6.166

Review 3.  Genetics of breast cancer bone metastasis: a sequential multistep pattern.

Authors:  Hassan Fazilaty; Parvin Mehdipour
Journal:  Clin Exp Metastasis       Date:  2014-02-04       Impact factor: 5.150

Review 4.  Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.

Authors:  Julieta Afonso; Lúcio L Santos; Adhemar Longatto-Filho; Fátima Baltazar
Journal:  Nat Rev Urol       Date:  2020-01-17       Impact factor: 14.432

5.  Perturbation of phosphoglycerate kinase 1 (PGK1) only marginally affects glycolysis in cancer cells.

Authors:  Chengmeng Jin; Xiaobing Zhu; Hao Wu; Yuqi Wang; Xun Hu
Journal:  J Biol Chem       Date:  2020-03-26       Impact factor: 5.157

Review 6.  PPARs and Tumor Microenvironment: The Emerging Roles of the Metabolic Master Regulators in Tumor Stromal-Epithelial Crosstalk and Carcinogenesis.

Authors:  Hong Sheng Cheng; Yun Sheng Yip; Eldeen Kai Yi Lim; Walter Wahli; Nguan Soon Tan
Journal:  Cancers (Basel)       Date:  2021-04-29       Impact factor: 6.639

7.  Therapeutic implications of targeting energy metabolism in breast cancer.

Authors:  Meena K Sakharkar; Babita Shashni; Karun Sharma; Sarinder K Dhillon; Prabhakar R Ranjekar; Kishore R Sakharkar
Journal:  PPAR Res       Date:  2013-02-03       Impact factor: 4.964

8.  Coffee component hydroxyl hydroquinone (HHQ) as a putative ligand for PPAR gamma and implications in breast cancer.

Authors:  Babita Shashni; Karun Sharma; Rumani Singh; Kishore R Sakharkar; Sarinder K Dhillon; Yukio Nagasaki; Meena K Sakharkar
Journal:  BMC Genomics       Date:  2013-10-16       Impact factor: 3.969

9.  High Expression of Pyruvate Kinase M2 is Associated with Chemosensitivity to Epirubicin and 5-Fluorouracil in Breast Cancer.

Authors:  Yang Lin; Feng Lv; Fangfang Liu; Xiaojing Guo; Yu Fan; Feng Gu; Jun Gu; Li Fu
Journal:  J Cancer       Date:  2015-09-15       Impact factor: 4.207

Review 10.  PPAR agonists as effective adjuvants for COVID-19 vaccines, by modifying immunogenetics: a review of literature.

Authors:  Antoine Fakhry AbdelMassih; Rahma Menshawey; Jumana H Ismail; Reem J Husseiny; Yousef M Husseiny; Shenoda Yacoub; Aya Kamel; Rafeef Hozaien; Elaria Yacoub; Esraa Menshawey; Abanoub Abdelmalek; Ahmed Abouelazaem; Ahmed Elhatw; Ahmed Aboelmaaty; Alaaelrahman Shahib; Amany Mansour; Aya Kamal; Basant Mohamed; Bemen Atif; Beshoy Ghabreal; Catherine Abdelmalak; David Ibrahim; Ebtesam Elsaify; Farah Magdy; Farid G Hanna; Hadeer Hafez; Hafsa Dahir; Kerlos Merhom; Maram Ahmed; Mariam Bishara; Mina Tawfik; Mina Youssef; Mohamed El Sharnouby; Mourad Hamouda; Musheera Ammar; Nada Ali; Nada Daniel; Nadine El-Husseiny; Noha Abdelraouf; Nuran K Abdelhameed; Radwa Ahmed; Radwa Othman; Rahma Mohamadein; Rana Allam; Rana Elgendy; Rana Shebl; Saged Elsherbiney; Sarah Fouad; Sara Emel; Sara Owais; Sarah Hetta; Samah El-Saman; Shaimaa Abdelalim; Sherin Galal; Yara Asar; Yara Osman; Yasmeen Khalaf; Youstina Aziz; Yousra Khafagy; Nervana Gamal; Biagio Castaldi
Journal:  J Genet Eng Biotechnol       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.